Skip to main content
Home / Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Volume 26, Number 2

Open Access [ARTICLE WITHDRAWN] Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia via Targeting miR-184

Notice

This article has been taken down at the request of the publisher.

Please contact the publisher for further information.



THIS ARTICLE WAS WITHDRAWN BY THE PUBLISHER IN 03/2021

We submitted a manuscript entitled "Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia via Targeting miR-184", which was published in the 26(2) issue of Oncology Research. But now we found some inaccuracies in this manuscript. So after carefully thinking, we are going to withdraw manuscript and try to give more precise model. Thus we decided to withdraw this manuscript with great pity. We sincerely say sorry for all the staffs involved this manuscript because of our action. All authors agree to withdraw this manuscript.

Thank you very much for your time and kind consideration.

Thanks for your time and best wishes.

Li Jingdong.

Keywords: Leukemia; Long noncoding RNAs (lncRNAs); Maternally expressed gene 3 (MEG3); miR-184

Document Type: Research Article

Publication date: 05 March 2018

More about this publication?

  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

    From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content